论文部分内容阅读
目的比较阿托伐他汀和普伐他汀治疗原发性高脂血症的疗效和安全性。方法 61例原发性高脂血症的患者随机分两组 ,阿托伐他汀组 3 2例 ,10mg/d口服 ;普伐他汀组 2 9例 ,2 0mg/d口服。疗程 8周 ,观察降脂疗效和不良反应。结果阿托伐他汀组总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDL C)与治疗前比较均有显著下降 (P <0 .0 1) ,阿托伐他汀组降低TC、LDL C的作用优于普伐他汀组 (P <0 .0 5 )。两组不良反应相似 ,均较轻微。结论阿托伐他汀治疗原发性高脂血症的疗效明显优于普伐他汀 ,不良反应轻微 ,耐受性良好
Objective To compare the efficacy and safety of atorvastatin and pravastatin in the treatment of primary hyperlipidemia. Methods Sixty-one patients with primary hyperlipidemia were randomized into two groups. Atorvastatin group (n = 32) was treated with 10 mg / d orally. In the pravastatin group, 29 patients were given orally with 20 mg / d. Treatment for 8 weeks, observed lipid-lowering efficacy and adverse reactions. Results The total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL C) in Atorvastatin group were significantly decreased compared with those before treatment (P <0.01). Atorvastatin group Lower TC, LDL C than pravastatin group (P <0.05). Adverse reactions were similar in both groups, were mild. Conclusions Atorvastatin is superior to pravastatin in the treatment of primary hyperlipidemia with mild adverse reactions and good tolerability